PTH and chronic kidney disease: While demonstrated to be highly effective in reducing PTH levels, calcimimetics are only indicated for CKD patients on haemodialysis, with studies of these agents in CKD Stage G3–G4 showing an increased risk of hypocalcaemia and hyperphosphataemia in these patients [7, 64, 65].